Cipher Pharmaceuticals Stock Current Valuation
| CPH Stock | CAD 14.86 0.30 2.06% |
Valuation analysis of Cipher Pharmaceuticals helps investors to measure Cipher Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 23rd of November 2024, Enterprise Value Over EBITDA is likely to drop to 4.69. In addition to that, Enterprise Value Multiple is likely to drop to 4.69. Fundamental drivers impacting Cipher Pharmaceuticals' valuation include:
Price Book 2.697 | Enterprise Value 423.9 M | Enterprise Value Ebitda 24.0336 | Price Sales 14.3706 | Forward PE 11.7233 |
Overvalued
Today
Please note that Cipher Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Cipher Pharmaceuticals is based on 3 months time horizon. Increasing Cipher Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cipher Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cipher Stock. However, Cipher Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.86 | Real 12.91 | Hype 14.9 | Naive 17.35 |
The intrinsic value of Cipher Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cipher Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cipher Pharmaceuticals helps investors to forecast how Cipher stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cipher Pharmaceuticals more accurately as focusing exclusively on Cipher Pharmaceuticals' fundamentals will not take into account other important factors: Cipher Pharmaceuticals Company Current Valuation Analysis
Cipher Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cipher Pharmaceuticals Current Valuation | 423.92 M |
Most of Cipher Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cipher Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cipher Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Cipher Pharmaceuticals is extremely important. It helps to project a fair market value of Cipher Stock properly, considering its historical fundamentals such as Current Valuation. Since Cipher Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cipher Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cipher Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cipher Pharmaceuticals has a Current Valuation of 423.92 M. This is 97.05% lower than that of the Pharmaceuticals sector and 94.3% lower than that of the Health Care industry. The current valuation for all Canada stocks is 97.45% higher than that of the company.
Cipher Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cipher Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cipher Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cipher Pharmaceuticals by comparing valuation metrics of similar companies.Cipher Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Cipher Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cipher Pharmaceuticals from analyzing Cipher Pharmaceuticals' financial statements. These drivers represent accounts that assess Cipher Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cipher Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 31.0M | 19.7M | 37.2M | 304.5M | 106.4M | 69.3M | |
| Enterprise Value | 34.2M | 12.4M | 17.2M | 276.1M | 66.9M | 60.9M |
Cipher Fundamentals
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0506 | ||||
| Profit Margin | 0.60 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 423.92 M | ||||
| Shares Outstanding | 25.59 M | ||||
| Shares Owned By Insiders | 42.00 % | ||||
| Shares Owned By Institutions | 1.50 % | ||||
| Number Of Shares Shorted | 87.99 K | ||||
| Price To Earning | 21.55 X | ||||
| Price To Book | 2.70 X | ||||
| Price To Sales | 14.37 X | ||||
| Revenue | 21.16 M | ||||
| Gross Profit | 16.68 M | ||||
| EBITDA | 10.48 M | ||||
| Net Income | 20.38 M | ||||
| Cash And Equivalents | 9.25 M | ||||
| Cash Per Share | 0.34 X | ||||
| Total Debt | 353 K | ||||
| Debt To Equity | 62.30 % | ||||
| Current Ratio | 1.06 X | ||||
| Book Value Per Share | 3.86 X | ||||
| Cash Flow From Operations | 16 M | ||||
| Short Ratio | 2.39 X | ||||
| Earnings Per Share | 0.90 X | ||||
| Target Price | 16.7 | ||||
| Beta | 1.17 | ||||
| Market Capitalization | 380.26 M | ||||
| Total Asset | 86.03 M | ||||
| Retained Earnings | 66.27 M | ||||
| Working Capital | 43.02 M | ||||
| Net Asset | 86.03 M |
About Cipher Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cipher Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cipher Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cipher Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cipher Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cipher Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cipher Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Cipher Stock
| 0.77 | AMZN | Amazon CDR | PairCorr |
| 0.64 | BNS | Bank of Nova Scotia | PairCorr |
| 0.64 | BMO | Bank of Montreal | PairCorr |
| 0.42 | RY | Royal Bank | PairCorr |
| 0.4 | TD-PFI | Toronto Dominion Bank | PairCorr |
The ability to find closely correlated positions to Cipher Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cipher Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cipher Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cipher Pharmaceuticals to buy it.
The correlation of Cipher Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cipher Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cipher Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cipher Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.